Community Acquired Pneumonia - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Community Acquired Pneumonia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Community Acquired Pneumonia - Pipeline Review, H1 2015', provides an overview of the Community Acquired Pneumonia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Community Acquired Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Pneumonia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Community Acquired Pneumonia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Community Acquired Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Community Acquired Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Community Acquired Pneumonia Overview 6
Therapeutics Development 7
Pipeline Products for Community Acquired Pneumonia - Overview 7
Pipeline Products for Community Acquired Pneumonia - Comparative Analysis 8
Community Acquired Pneumonia - Therapeutics under Development by Companies 9
Community Acquired Pneumonia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Community Acquired Pneumonia - Products under Development by Companies 14
Community Acquired Pneumonia - Companies Involved in Therapeutics Development 15
Actavis plc 15
AstraZeneca PLC 16
Biotest AG 17
C10 Pharma AS 18
Kyorin Pharmaceutical Co., Ltd. 19
Paratek Pharmaceuticals, Inc. 20
TaiGen Biotechnology Co., Ltd. 21
Takeda Pharmaceutical Company Limited 22
Community Acquired Pneumonia - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
BT-086 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
C-10 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ceftaroline fosamil - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dalbavancin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
KRPAM-1977X - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
nemonoxacin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
omadacycline - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules for SSTI and CAP Infections - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ticagrelor - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Community Acquired Pneumonia - Recent Pipeline Updates 50
Community Acquired Pneumonia - Dormant Projects 65
Community Acquired Pneumonia - Discontinued Products 66
Community Acquired Pneumonia - Product Development Milestones 67
Featured News & Press Releases 67
Oct 03, 2014: FDA Grants Durata Therapeutics a Special Protocol Agreement for Its Phase 3 Study of DALVANCE in Hospitalized Community-Acquired Pneumonia 67
Sep 11, 2013: New Antibiotic Shows Promise for Treating MRSA Pneumonia 67
May 16, 2013: TaiGen Biotechnology Submits New Drug Application For Nemonoxacin In Taiwan And China 68
Aug 28, 2012: European Commission Approves Zinforo To Treat Skin Infections Or Community Acquired Pneumonia 69
Jun 22, 2012: CHPM Adopts Positive Opinion For Zinforo For Treatment Of Complicated Skin And Soft Tissue Infections 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Tables
Number of Products under Development for Community Acquired Pneumonia, H1 2015 7
Number of Products under Development for Community Acquired Pneumonia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Community Acquired Pneumonia - Pipeline by Actavis plc, H1 2015 15
Community Acquired Pneumonia - Pipeline by AstraZeneca PLC, H1 2015 16
Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2015 17
Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H1 2015 18
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 19
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 20
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 21
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Community Acquired Pneumonia Therapeutics - Recent Pipeline Updates, H1 2015 50
Community Acquired Pneumonia - Dormant Projects, H1 2015 65
Community Acquired Pneumonia - Discontinued Products, H1 2015 66